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Three TNF-A-INhIbITorS For TreATMeNT oF rheuMAToId ArThrITIS, 
ANkyloSINg SPoNdylITIS ANd PSorIATIc ArThrITIS
Ivakhnenko O.1, Rebrova O.2, Avxentyeva M.3, Khachatryan G.1
1Autonomous non-profit organization “National Centre for Health Technology Assessment”, 
Moscow, Russia, 2Pirogov Russian National Research Medical University, Moscow, Russia, 3The 
Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia
Objectives: To perform pharmacoeconomic analysis of golimumab (GOL) vs 
adalimumab (ADA) and infiliximab (INF) for rheumatoid arthritis (RA), ankylosing 
spondylitis (AS) and psoriatic arthritis (PA) in Russia MethOds: Indirect compar-
ison demonstrated that compared drugs have similar efficacy and safety. Cost-
minimization analysis was performed to compare the cost for 1-year treatment with 
GOL, ADA and INF in doses according to the approved recommendations. Expected 
cost for treating all eligible patients with RA, AS and PA with TNF-α -inhibitors in 
Russia were calculated in a model, assuming that INF is used in the 1st line therapy 
during one year and ADA or GOL in the 2d line therapy during the 2d year. Number 
of patients to be treated with TNF-α -inhibitors was calculated based on state sta-
tistical data and data on the percentage of patients who do not respond to therapy 
with synthetic disease-modifying antirheumatic drugs (DMARDs) and first-line 
biologic DMARDs from clinical trials. Results: INF dosing regimen is different 
for RA and other rheumatic diseases, 1 year treatment with INF costs € 16,212 for 
RA and € 24,319 for AS and PA. GOL and ADA have the same dosing regimen for all 
rheumatic diseases and costs € 16,544 and € 24,243 per year correspondingly. If all 
eligible patients with rheumatic diseases in Russia receive biologic DMARDs when 
necessary, treatment with GOL in the 2d line is less expensive than ADA, difference 
in costs is € 89,062,427 (for all eligible patients per year). It allows treating additional 
4959 patients RA, 278 AS patients and 147 PA patients per year. cOnclusiOns: GOL 
is cost-saving vs ADA for the 2d line therapy of rheumatic diseases in Russia. 1-year 
treatment with GOL is less expensive that INF for AS and PA and may be considered 
as the 1st line option.
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PhArMAcoecoNoMIc ANAlySIS oF AbATAcePT For TreATMeNT oF AdulTS 
wITh rheuMAToId ArThrITIS IN ruSSIA
Gerasimova K.1, Avxentyeva M.2, Goryaynov S.3, Rebrova O.4
1The First Moscow State Medical University named after I.M. Sechenov, Moscow, Russia, 2The 
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Objectives: to conduct a pharmacoeconomic analysis of abatacept vs etaner-
cept, tocilizumab and adalimumab for rheumatoid arthritis (RA) in adult patients, 
resistant to methotrexate therapy, in Russia. MethOds: Indirect comparison of 
clinical efficacy of abatacept, etanercept, tocilizumab and adalimumab was per-
formed. Data on safety from clinical studies and meta-analysis was analyzed. The 
differences in the direct medical costs for compared biological drugs (BD) in adult 
patients with RA were calculated using the cost-minimisation analysis. The cost 
of abatacept vs etanercept and tocilizumab were calculated on the basis of the 
registered manufacture’s prices for vital and essential drugs (VED) in 2012. The 
costs of abatacept vs adalimumab were calculated based on the price of tender 
purchases in 2011 (adalimumab is not included into the VED List, and its price is 
not registered). The costs of day care for patients during the BD administration 
were calculated based on the cost norms per volume of medical care approved by 
the Program of State Guarantees for the provision of free medical care to Russian 
citizens in 2012. The calculations were performed over the BD application period 
for 2 years. Results: Indirect comparison showed no statistically significant dif-
ferences in the efficacy of compared BD. There was no data about clinically mean-
ingful differences in safety. The use of abatacept is less costly than etanercept 
and tocilizumab when registered manufacture’s prices are used for cost estima-
tion. The difference in costs (in favor of abatacept) amounted to 1431.34 EUR and 
16058.34 EUR per patient per 2 years respectively. Abatacept is less costly than 
adalimumab (the costs are calculated based on prices of tender purchases in 2011): 
the difference in costs amounted to 1502.07 EUR per patient per 2 years in favor 
of abatacept. cOnclusiOns: Abatacept is a cost-saving option compared with 
etanercept, tocilizumab and adalimumab.
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curreNT ANd FuTure STrATegy For oSTeoPoroSIS ScreeNINg ANd 
dIAgNoSTIcS: coST-eFFecTIveNeSS oF FrAx wITh or wIThouT PulSe-
echo ulTrASouNd MeASureMeNT oF boNe MINerAl deNSITy ANd dxA oN 
deMANd
Asseburg C.1, Riekkinen O.2, Karjalainen J.K.2, Kröger H.3, Soini E.J.1
1ESiOR Oy, Kuopio, Finland, 2Bone Index Finland, Kuopio, Finland, 3Kuopio University Hospital, 
Kuopio, Finland
Objectives: Over 75% of osteoporotic patients are not diagnosed with osteoporo-
sis and do not receive treatment because effective on-site diagnostics is lacking in 
primary care facilities. We compare the cost-effectiveness of two pathways of osteo-
porosis diagnosis: 1) Fracture Risk Assessment Tool (FRAX) followed by pocket size 
pulse-echo ultrasound device (Bindex®) followed by Dual-energy X-ray absorptiom-
etry (DXA) when needed (“proposed”), and 2) FRAX followed by DXA when needed 
(“guideline”). MethOds: A new Markov model of preventive osteoporosis treatment 
(assumptions: generic alendronate treatment; efficacy based on published meta-
analysis and modified by compliance/persistence; wrist, vertebral, hip and other frac-
tures included; Finnish health care payer perspective with 10-year timeframe and 3% 
discounting per annum) was extended to include the proposed pathway and osteo-
porosis screening/diagnosis in terms of sensitivity/specificity. FRAX with body mass 
index and age dependent National Osteoporosis Guideline Group thresholds was the 
initial screening tool common to both pathways. Bindex® was calibrated to 90% sen-
sitivity and specificity thresholds (International Society for Clinical Densitometry). In 
the proposed pathway, only the patients with Bindex result between these calibration 
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ASSeSSMeNT oF The ecoNoMIc IMPAcT oF belIMuMAb For The TreATMeNT 
oF SySTeMIc luPuS erITheMAToSuS IN The ITAlIAN SeTTINg: A coST-
eFFecTIveNeSS ANAlySIS
Turchetti G.1, Pierotti F.1, Palla I.1, Stragliotto E.2, Porcasi R.2, Pippo L.2
1Scuola Superiore Sant’Anna, Pisa, Italy, 2GlaxoSmithKline, Verona, Italy
Objectives: Systemic Lupus Erythematosus (SLE) is a chronic non-organ spe-
cific autoimmune disease and is characterized by a dysregulation of the immune 
system that involves many organs and systems. It affects about 28,500 people 
in Italy, especially women of childbearing age (female-male ratio 9:1) that may 
have a compromised functional state and a decreased quality of life. The purpose 
of this analysis is to determine the cost-effectiveness of belimumab, a new bio-
logical treatment specifically developed for the treatment of SLE, in the Italian 
setting. MethOds: A cost-effectiveness micro simulation model with a lifetime 
horizon was adapted to the Italian setting. The analysis compares the standard 
of care (SoC) alone vs belimumab plus SoC from the perspective of the National 
Healthcare System. Clinical-economic consequences of the therapy and of the 
development of organ damage were calculated. When available, Italian data were 
used, otherwise UK costs were transformed into euros using the purchasing-power 
parity approach. The utility values were based on the EQ-5D of belimumab clini-
cal trials (BLISS 52 and 76). The results were discounted by 3% for both costs and 
effects. It was considered a duration of treatment with belimumab of 6 years and 
it was assumed that the drug is used with wastage. Results: The results of the 
cost-effective analysis in terms of cost per life year gained (ICER) and cost per QALY 
(ICUR) were € 22,990 and € 32,859 respectively. These values drop to € 20,119 and 
€ 28,754 respectively when indirect costs are included. cOnclusiOns: In this 
analysis, the results of ICER and ICUR show that belimumab is cost-effective in 
the Italian setting, according to the guidelines of the Italian Association of Health 
Economics (€ 25-40,000/QALY).
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TocIlIzuMAb IN PolyArTIculAr JuveNIle IdIoPAThIc ArThrITIS – A coST-
uTIlITy Model For The uNITed kINgdoM
Chang S.1, Sawyer L.1, Dejonckheere F.2, van Suijlekom-Smit L.W.3, Anink J.3, 
Diamantopoulos A.1
1Symmetron Limited, Elstree, UK, 2F. Hoffmann-La Roche Ltd., Basel, Switzerland, 3Erasmus MC 
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Objectives: To evaluate the cost-effectiveness of tocilizumab (TCZ) in the treat-
ment of polyarticular juvenile idiopathic arthritis (pJIA) in the United Kingdom 
(UK). MethOds: An individual sampling model was developed to reflect the health 
care system and treatment pathway in the UK. Benefits were measured in terms of 
Quality Adjusted Life years (QALYs) and were derived from HUI3 data collected by 
the Dutch Arthritis and Biologicals in Children (ABC) Register [Prince et al., 2011]. 
Costs were calculated from a National Health Service and Personal Social Services 
perspective. The analysis calculated incremental costs and benefits associated with 
the addition of first line TCZ to the standard care pathway involving etanercept 
(ETN), adalimumab (ADA), and abatacept (ABA). The economic model used efficacy 
inputs derived from an indirect comparison of TCZ and ADA [Sawyer et al., 2013]. 
Due to fundamental differences in the clinical trial populations and trial design, it 
was not possible to compare the response rates of TCZ with ETN and ABA. Therefore 
in the absence comparative data, the economic analysis assumed response rates 
for ETN and ABA were similar to ADA. Longer-term treatment discontinuation was 
linked to level of response and assumed to be independent of treatment. Results: 
Base case results estimated incremental costs of approximately £1,750 and incre-
mental QALYs of 0.1011. The incremental cost-effectiveness ratio (ICER) was £17,000 
per QALY gained. cOnclusiOns: The results of this analysis suggest that TCZ rep-
resents an efficacious and cost-effective addition to the current standard of care for 
treating pJIA patients in the UK.
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coST-MINIMIzATIoN ANAlySIS oF SubcuTANeouS AbATAcePT IN The 
TreATMeNT oF rheuMAToId ArThrITIS IN SPAIN
Ariza-Ariza R.1, van Walsem A.2, Canal Fontcuberta C.3, Roldán Acevedo C.4,  
Betegón Nicolás L.3, Oyagüez Martín I.4, Janssen K.2
1Hospital Universitario Virgen Macarena, Sevilla, Spain, 2Mapi, Houten, Spain, 3Bristol-Myers 
Squibb, Madrid, Spain, 4Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
Objectives: To compare the cost of using subcutaneous abatacept (SC ABA) versus 
other first-line biological disease-modifying antirheumatic drugs (DMARDs) avail-
able in Spain, in the treatment of patients with rheumatoid arthritis (RA) who have 
failed an initial treatment with methotrexate (MTX). MethOds: With regards to 
efficacy and safety outcomes, SC ABA was considered non-inferior vs intravenous 
ABA (IV ABA), adalimumab (ADA), certolizumab pegol (CZP), etanercept (ETN), goli-
mumab (GLM), infliximab (IFX) and tocilizumab (TCZ), based on results of an indirect 
comparison using mixed treatment analysis. Therefore a cost- minimization analy-
sis for a 3 year time horizon was developed. The perspective was that of the Spanish 
National Health System (NHS). Pharmaceutical and administration costs (€ , 2013) of 
all biological DMARDs which are available in Spain as first-line treatment after MTX 
were considered. Drug costs were included in terms of ex-factory price with man-
datory rebate. Administration costs were obtained from local published data. The 
analysis was developed for an average patient weight of 70 kg. A 3% annual discount 
rate was applied. Deterministic and probabilistic sensitivity analyses were per-
formed. Results: SC ABA treatment was associated with a yearly cost of € 11,521.36 
per patient during the first year of treatment and € 11,002.23 in subsequent years. 
The total 3-year cost of SC ABA was € 32,138.43 per patient, proving to be cost saving 
versus most of the other biological DMARDs. In all cases, pharmaceutical costs lead 
to more than 85% of total disease management costs. Sensitivity analyses proved 
the model to be robust. cOnclusiOns: According to these results, SC ABA would 
lead to cost-savings versus IV ABA, ADA, CZP, ETN, GLM and TZC in the management 
of RA patients initiating treatment with biological DMARDs.
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modifying antirheumatic drugs (tDMARDs) and are intolerant or contraindicated 
to methotrexate (MTX). MethOds: A patient-level simulation model was applied 
to project lifetime costs and outcomes for 10.000 patients from a payer’s perspec-
tive. The analysis compared a standard treatment pathway (STP) (adalimumab, 
etanercept and palliative care) with a similar pathway initialized with tocilizumab 
(TCZ). Disease severity was reflected by Health Assessment Questionnaire (HAQ) 
scores. As primary efficacy outcomes, American College of Rheumatology (ACR) 
response rates were used. Patient characteristics (age, gender and baseline HAQ 
score) and TCZ efficacy data were derived from the ADACTA trial, whereas effi-
cacy data for the remaining DMARDs were derived from a network meta-analysis 
of each medication’s trial outcomes. A mapping model transformed HAQ scores 
into QALYs. Clinical practice standards were defined by an expert panel of Greek 
Rheumatologists. Costs for pharmaceuticals and resource unit costs were obtained 
from official (Social Insurance) price lists. A discount rate of 3% was used for both 
costs and QALYs. Results: Results indicate that a treatment sequence starting 
with TCZ yields 1.17 more QALYs (9.38 vs. 8.21) for an additional cost of € 33,145 
(€ 125,409 vs. € 92,264) compared to the STP. The Incremental Cost – Effectiveness 
Ratio (ICER) was 28,325.5€ /QALY gained. Sensitivity Analysis confirms robustness 
of findings below a threshold of € 45.000. cOnclusiOns: The results of the analy-
sis suggest that TCZ as a first-line biologic drug can be a cost-effective treatment 
option for the management of active RA in patients intolerant or contraindicated 
to MTX.
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heAlTh ecoNoMIc ModellINg oF SequeNTIAl TherAPIeS For 
rheuMAToId ArThrITIS: A SySTeMATIc revIew
Tosh J., Stevenson M., Akehurst R.
University of Sheffield, Sheffield, UK
Objectives: A systematic review was conducted to: 1) Identify economic evalu-
ations of therapies for rheumatoid arthritis (RA), and 2) assess and critique how 
sequential therapies were modelled and evaluated. MethOds: Systematic 
searches of ten databases were undertaken to identify published economic evalua-
tions of disease modifying therapies for RA. Searches were undertaken in February 
2013, with no date restriction. Studies were included if they reported a full compar-
ative economic evaluation. Identified studies were appraised using the Drummond 
economic evaluation checklist. Data extracted included economic evaluation data, 
along with data relating to sequential treatments. Data on the modelling methods 
used were also extracted, to identify how data sources were synthesised. The 
systematic review was conducted to the PRISMA standards. Results: Fifty-seven 
studies were identified. 43 (75%) were cost-utility analyses. 11 (19%) had a UK 
perspective, and 11 (19%) had a US perspective. The remainder were mainly under-
taken within Europe (26 (46%) studies). There was a distinction between studies 
in recent-onset RA (14 (25%)), and those in established RA (42 (74%)). One study 
(1%) was unclear. The review identified approximately 30 RA treatments. Using 
individual level modelling was associated with improved quality of the evaluation 
and the ability to evaluate sequences. Reporting about the impact of future treat-
ments on costs and health benefits was poor. When downstream treatments were 
modelled, the evidence used was often poorly reported. No study considered iden-
tifying the optimal sequence of treatments given a set of alternative treatments. 
Where models have been developed that consider a lifelong time horizon and 
downstream treatment sequences, evidence gaps were identified. cOnclusiOns: 
The review has identified that methods have not been consistently applied, which 
has led to varied estimates of cost-effectiveness. Sequences of treatments have 
not been appropriately considered and modelled, potentially biasing estimates 
of cost-effectiveness.
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coST-uTIlITy ANAlySIS oF TocIlIzuMAb IN coMbINATIoN wITh 
MeThoTrexATe verSuS STANdArd oF cAre For The TreATMeNT oF 
rheuMAToId ArThrITIS IN greece
Athanasakis K.1, Konstantopoulou T.2, Tarantilis F.1, Tsalapati K.1, Vritzali E.3, Kyriopoulos J.1
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Objectives: Rheumatoid Arthritis (RA) is a chronic, inflammatory disease affecting 
0.68% of the adult population in Greece. RA is associated with a lowered quality of 
life and a serious economic burden. This study aims to evaluate the cost-effective-
ness of adding tocilizumab to a treatment sequence on a background of methotrex-
ate (MTX) for patients with active RA, who had an inadequate response to one or 
more traditional disease-modifying antirheumatic drugs (tDMARDs). MethOds: A 
patient-level simulation model was applied to project lifetime costs and outcomes 
for 10.000 patients from a payer’s perspective. The analysis compared a standard 
treatment pathway (STP) (Adalimumab, Etanercept, Abatacept and Palliative care 
along with MTX) with a similar pathway initialized with Tocilizumab (TCZ). Disease 
severity was reflected by Health Assessment Questionnaire (HAQ) scores. As pri-
mary efficacy outcomes American College of Rheumatology (ACR) response rates 
were used . Patient characteristics (age, gender and baseline HAQ score) and drug 
efficacy for TCZ were obtained by an analysis of pooled data from three phase-III 
clinical trials. Efficacy data for comparators were derived from indirect compari-
sons. A mapping model transformed HAQ scores into QALYs. Standards regard-
ing clinical practice were defined by an expert panel of Greek Rheumatologists. 
Costs for pharmaceuticals and resource unit costs were derived from official (Social 
Insurance) price lists. A discount rate of 3% was used for costs and QALYs. Results: 
Results indicate that a treatment sequence starting with TCZ yields 0.79 more 
QALYs (11.68 vs. 10.89) for an additional cost of € 21,174 (€ 168,963 vs. € 147,788) 
compared to STP. The Incremental Cost – Effectiveness Ratio was 26,686€ /QALY 
gained. Sensitivity Analysis confirms robustness of findings below a threshold of 
€ 45.000. cOnclusiOns: The results of the analysis suggest that TCZ, combined 
with MTX, as a first-line biologic drug can be a cost-effective treatment option for 
the management of active RA compared to STP.
thresholds (32,6% of the patients) required a DXA measurement to verify the diagnosis 
of osteoporosis. Cost-effectiveness was assessed in five patient cohorts: women (BMI 
24 kg/m2) aged 65 years with previous fracture and 75 or 85 years with and without 
previous fracture. Results: Among the cohorts modeled, the average screening cost 
saved with Bindex® including proposed pathway in comparison to current guideline 
pathway were around € 230/patient. At a cost of € 50/screen, the probability that the 
pathway including Bindex® was cost-effective compared to the current pathway was 
100% in all patient cohorts. Bindex® including pathway appeared to be cost-effective 
at prices as high as € 100/screen. cOnclusiOns: Bindex® including pathway appears 
to be cost-saving strategy compared to the current and recommended Finnish osteo-
porosis diagnosis and care pathway.
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A Model oF The coST eFFecTIveNeSS oF INFlIxIMAb For The TreATMeNT 
oF Severely AcTIve ulcerATIve colITIS, IN chIldreN ANd AdoleSceNTS 
Aged 6 To 17 yeArS, who hAve hAd AN INAdequATe reSPoNSe To 
coNveNTIoNAl TherAPy
Farrell J.1, Jiang Y.2, Chaudhary M.A.3, Sheppard O.1, Gathany T.4, Fan T.5
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Whitehouse Station, NJ, USA
Objectives: To evaluate the cost-effectiveness of Infliximab (IFX) treatment in severe, 
active paediatric ulcerative colitis (pUC). MethOds: A Markov model was constructed 
based upon the literature, to model the progression of a cohort of pUC patients treated 
with IFX and ciclosporin (CIC) used off-label in the rescue therapy setting. The transi-
tion probabilities were estimated from the IFX phase III trials (T72, ACT1 and ACT2).
The comparative efficacy was incorporated by using the odds ratio for IFX vs. CIC from 
a head to head trial in adults (Laharie et al). Utility weights from observational studies 
(SOLUTION and Arseneau et al) were assigned to the health states within the Markov 
process. Incremental cost-effectiveness ratios (ICERs) were estimated with a one year 
time horizon. Uncertainty around key variables was explored through deterministic 
sensitivity analysis. Results: Compared to CIC in the rescue therapy setting, IFX 
was a dominant treatment option (produced more QALYs at a lower cost). The results 
were sensitive to the number of days patients were hospitalised for each treatment, 
the comparative rates of adverse events and altering the odds ratio for comparative 
effectiveness. cOnclusiOns: IFX is a highly effective and well-tolerated therapy 
for the treatment of paediatric patients with severely active ulcerative colitis. IFX is 
the only biologic treatment licensed for this population, and is cost-effective when 
compared to the commonly used off-licence treatment CIC.
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coST-uTIlITy oF rheuMAToId ArThrITIS MoNoTherAPy wITh 
TocIlIzuMAb IN SPAIN
Benito Ruiz P.1, Navarro Sarabia F.2, Gomez Reino J.3, Poveda J.4, Alvaro Gracia J.5,  
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Objectives: Analyze Tocilizumab (TCZ) monotherapy cost-utility for moderate/ 
severe rheumatoid arthritis in patients who are intolerant/contraindicated to MTX, com-
pared with two standard treatment sequences: comparison 1: Etanercept-Adalimumab-
Certolizumab-Support treatment vs. Tocilizumab-Etanercept-Adalimumab-Support 
treatment, and comparison 2: Adalimumab-Etanercept-Certolizumab- Support treat-
ment vs. Tocilizumab-Adalimumab-Etanercept-Support treatment. MethOds: A life 
time micro-simulation model with 6 months cycles was performed in order to 
calculate the incremental cost-effectiveness ratio of the TCZ treatment sequences 
vs. standards sequences, which were determined by an expert panel of Spanish 
rheumatologists. Demographic data on age, HAQ score and sex were obtained 
from the ADACTA trial, while body weight data was obtained from the PRAXIS 
study. The efficacy data (ACR clinical response) were obtained from the pivotal 
clinical trial of each drug. Utilities were calculated from the relationship between 
ACR response, HAQ score and EQ5D instrument, according to the VACAR study, 
conducted in the Spanish population. The analysis was done from National Health 
System (NHS) perspective. Unit costs (€ ; 2012) were obtained from Spanish sources. 
Annual discount rate was 3.5% for costs and outcomes. Probabilistic sensitivity 
analyses were performed. Results: TCZ sequences generated more costs per 
patient than the standard sequence (€ 7,107 in comparison 1; € 6,087 in comparison 
2). However, the TCZ sequence generated more QALYs than the standard sequence 
(0.330 in comparison 1 and 0.297 in comparison 2). The cost of gaining a QALY with 
TCZ sequences versus the standard sequence was € 21,529 (comparison 1) and € 
20,496 (comparison 2). According to probabilistic sensitivity analyses, the prob-
ability that the TCZ sequences are cost effective is 86.8% for the comparison 1 and 
86.1% for the comparison 2. cOnclusiOns: In both comparisons, the analysis 
results indicate that the inclusion of TCZ monotherapy as first-line represents 
an effective and cost-effective alternative in Spain versus the current sequences 
used for the treatment of patients with rheumatoid arthritis and MTX intoler-
ance/contraindication.
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coST-uTIlITy ANAlySIS oF TocIlIzuMAb MoNoTherAPy verSuS STANdArd 
oF cAre For The TreATMeNT oF rheuMAToId ArThrITIS IN greece
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Objectives: Rheumatoid Arthritis (RA) is a chronic, inflammatory disease 
affecting 0.68% of the adult population in Greece. RA is associated with a lowered 
quality of life and a serious economic burden. This study aims to evaluate the 
cost-effectiveness of adding tocilizumab to a treatment sequence for patients with 
active RA, who had an inadequate response to one or more traditional disease-
